📰 Patrickc Reid News
Patrickc Reid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Patrickc Reid. Real-time updates on events, politics, business and more.
September 27, 2023
Discovering the Next Generation of Transformational Medicines Sustainability Report 2023 ...
July 25, 2023
TOKYO & KAWASAKI, Japan--(BUSINESS WIRE)--#proteindegrader--Astellas Pharma Inc. (TOKYO: 4503, President and CEO: Naoki Okamura, “Astellas”) and PeptiDream Inc. (TOKYO: 4587, President and CEO: Patrick C. Reid, “PeptiDream”) today announced a research collaboration and license agreement to discover novel protein deg...
June 13, 2023
Contribution to people around the world. Hearing a " thank you" from even one patient, is what we strive for. This is our Dream at... | June 13, 2023
May 18, 2023
Contributing to faster and more efficient drug discovery through process visualization and centralized data managementTOKYO, May 18, 2023 - (JCN Newswire) - Fujitsu today announced the commercial debut
April 7, 2023
Corporate Governance Report Date of last revision: April 7, 2023 PeptiDream Inc. Patrick C. Reid Representative... | April 7, 2023
April 5, 2023
News Release April 5, 2023 PeptiDream Inc https://www.peptidream.com ... | April 5, 2023
January 10, 2023
News Release January 10, 2023 PeptiDream Inc https://www.peptidream.com ... | January 10, 2023
January 30, 2021
Published: Jan 07, 2021 NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ("Kleo") that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven...
January 8, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleos laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to s...